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Abstract
Background: Nanoparticles are characterized by having a high surface area per mass. Particulate
surface area has been reported to play an important role in determining the biological activity of
nanoparticles. However, recent reports have questioned this relationship. This study was
conducted to determine whether mass of particles or surface area of particles is the more
appropriate dose metric for pulmonary toxicity studies. In this study, rats were exposed by
intratracheal instillation to various doses of ultrafine and fine carbon black. At 1, 7, or 42 days post-
exposure, inflammatory and cytotoxic potential of each particle type was compared on both a mass
dosage (mg/rat) as well as an equal surface area dosage (cm2 of particles per cm2 of alveolar
epithelium). In an additional study, the pulmonary responses to instillation of ultrafine carbon black
were compared to equivalent particle surface area doses of ultrafine titanium dioxide.
Results: Ultrafine carbon black particles caused a dose dependent but transient inflammatory and
cytotoxic response. On a mass basis, these responses were significantly (65 fold) greater than those
for fine sized carbon black. However, when doses were equalized based on surface area of particles
given, the ultrafine carbon black particles were only slightly (non-significantly) more inflammogenic
and cytotoxic compared to the fine sized carbon black. At one day post-exposure, inflammatory
potencies of the ultrafine carbon black and ultrafine titanium dioxide particles were similar.
However, while the pulmonary reaction to ultrafine carbon black resolved with time, the
inflammatory effects of ultrafine titanium dioxide were more persistent over a 42 day post-
exposure period.
Conclusion: These results indicate that for low toxicity low solubility materials, surface area of
particles administered rather than mass burden of particles may be a more appropriate dose metric
for pulmonary toxicity studies. In addition, ultrafine titanium dioxide appears to be more bioactive
than ultrafine carbon black on an equivalent surface area of particles delivered basis.
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Background
Nanotechnology is considered to be one of the world's
most promising new technologies, able to impact all
phases of life, just as the industrial revolution did in the
past two centuries. Utilizing the quantum properties of
atoms and molecules, nanotechnology proposes the con-
struction of novel molecular devices possessing extraordi-
nary properties. However, both epidemiological and
toxicological studies have contributed to a body of evi-
dence suggesting that nano or ultrafine particles may
induce or exaggerate a number of adverse biological
effects. It has been suggested that nanoparticles may inter-
fere with a number of molecular processes that should be
considered before such particles are brought into wide
commercial use [1].
Recent reports indicate that there can be considerable
potential for exposure to nanoparticles in the workplace,
especially during transfer, weighing, blending, and clean-
ing processes [2,3]. There is also interest and debate as to
whether low solubility, ultrafine particles should be regu-
lated differently from fine size particles of the same com-
position [4].
When evaluating exposure-dose-effect relationships of
inhaled particles, the definition and determination of
dose is crucial. Conventionally and conveniently, doses
usually are expressed in terms of particle mass. However,
when the pulmonary inflammatory potential of ultrafine
TiO2 was compared to fine size TiO2, particle surface area
was found to be a better predictor of bioactivity than par-
ticle mass burden delivered [5]. Studies, such as this with
nanoparticles, have been used to support the hypotheses
that particle surface area is important in determining
pathology [6] and inflammation [7]. However, recent
reports by Warheit et al. [8,9] have questioned this
hypothesis.
In general, for a fixed mass of particles, surface area
increases as particle size becomes smaller. Thus, a dose-
dependence on particle surface area may explain the
greater toxicity of nanoparticles compared with an equal
mass of fine particles of the same material [10,11]. The
finding that particle surface area rather than mass appears
to be a more appropriate metric of dose for predicting pul-
monary inflammation may imply a need to reconsider
exposure assessment practices for workplaces producing
or using nanoparticles. Currently, occupational exposure
limits for airborne dusts are defined in terms of mass per
m3 of air [11]. In support for the importance of exposure
standards, Serita et al. [12] conducted an experiment that
exposed rats to metallic ultrafine nickel at the Japanese
regulated occupational exposure level (OEL). This OEL
was based on data for fine nickel particles. However, the
exposure to OEL concentrations in the form of ultrafine
nickel caused severe lung injury after a single exposure
[12]. This finding supports the concept that surface area is
the dose measure that predicts pulmonary response,
rather than mass, and this has far reaching potential con-
sequences for occupational standards that are based on
mass [13].
Therefore, if in fact the inflammatory potential of a parti-
cle is driven by surface area rather than mass, then a given
airborne mass concentration of a material in the form of
fine particles could be much less inflammogenic than the
same airborne mass concentration of same material in the
form of ultrafine particles. Therefore, determining if high
surface area of nanoparticles is a driver for inflammatory
potential is of great importance for development of pro-
tective occupational health measures.
The present study aims to address the issue of whether, for
low toxicity low solubility materials, mass or surface area
of particles administered is a more appropriate dose met-
ric when assessing pulmonary toxicity of nanoparticles.
To address this question, in vivo intratracheal exposures
of rats to ultrafine carbon black (UFCB) and fine carbon
black (FCB) were conducted. Animals were exposed to
carbon black particles based on mass, and dose was nor-
malized to surface area of particles administered. Result-
ing pulmonary damage and inflammation were compared
on a mass dose and surface area of carbon black particles
administered to determine which dose metric was more
appropriate in evaluating nanoparticle toxicity. In addi-
tional experiments, the pulmonary activity of ultrafine
carbon black (UFCB) was compared to ultrafine titanium
dioxide (UFTiO2) on an equivalent surface area of parti-
cles delivered basis.
Results
UFCB and FCB suspended in acellular bronchoalveolar
lavage fluid (BALF) were administered to Fischer 344 rats
via intratracheal instillation to assess pulmonary toxicity.
The dose of particles administered was given on a mass
basis (mg/rat) and was also normalized to surface area of
particles administered per alveolar epithelial surface area
(cm2/cm2) using a value for alveolar epithelial surface
area in the rat reported by Stone et al. [14]. The surface
areas of the respective particles (269.0 m2/g for UFCB and
8.1 m2/g for FCB, respectively) were determined by the
BET gas absorption technique [15]. This comparison of
mass and surface area doses was conducted to assess
whether surface area of particles administered is the more
appropriate dose metric that should be considered when
assessing nanoparticle pulmonary toxicity parameters.
Pulmonary toxicity parameters measured included PMN
number, LDH activity, albumin levels, inflammatory
mediators (TNF-α, MIP-2, and IL-1β), as well as zymosan-Particle and Fibre Toxicology 2009, 6:15 http://www.particleandfibretoxicology.com/content/6/1/15
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stimulated chemiluminescence and NO dependent
chemiluminescence.
Comparison of pulmonary toxicity of UFCB and FCB
UFCB and FCB both caused a dose dependent increase in
the number of PMN obtained by BAL over the 42 day
post-exposure time period (Figure 1). The inflammatory
response for both UFCB and FCB was transient, decreas-
ing strikingly with time. However, the high dose of UFCB
and FCB still caused a significant increase in PMN number
over control at 1, 7 and 42 days post-exposure (Table 1).
Table 1 shows comparison on pulmonary toxicity param-
eters measured in control animals and for animals receiv-
ing the high doses (0.18 and 6.125 mg/rat) of UFCB and
FCB, respectively, at all post-exposure time points. At 1
day, 7 days and 42 days post-exposure, on a mass dose
basis, UFCB was significantly more inflammogenic than
FCB (Figure 1). When comparing the inflammogenic
response of UFCB exposure to FCB exposure, on a mass
dose basis (for example the PMN response to 3.06 mg/rat
FCB to 0.047 mg/rat UFCB from Figure 1), UFCB was
shown to be 65 times more potent than FCB at all post-
exposure times (Table 2). Table 2 shows The data were
analyzed to show the potency difference between UFCB
and FCB on a mass basis as well as the fold increase in pul-
monary toxicity response on a surface area basis, ie., sur-
face area of particles administered per surface area of
alveolar epithelium where the value for the alveolar epi-
thelial surface area for the rat was taken from Stone et al.
[14]. All post-exposure time points were analyzed and are
reported in the table. On a mass basis, the UFCB has much
greater potency than FCB, but when dose is normalized to
particle surface area administered the fold increase in
response between the UFCB and FCB is greatly reduced.
However, when the dose of particles was normalized to
surface area of particles administered the difference in
inflammogenic responses, assessed by PMN number, of
the two particle types became less. When comparing the
dose response curves assessing inflammation produced by
the UFCB and FCB exposures, normalized to surface area
of particles, a linear regression curve analysis with a 95%
confidence interval showed that there was no significant
difference between the two dose-response curves at any
post-exposure time (Figure 2). In fact, when dose was nor-
malized to surface area of particles administered, the
inflammogenic response elicited by UFCB was at most 2-
fold greater than the FCB response for all post-exposure
time points (Table 2).
In regards to the other pulmonary toxicity parameters
assessed for UFCB and FCB exposure, the same trend was
noted. LDH activity in BALF was measured to assess cellu-
lar cytotoxicity, and BALF albumin levels were analyzed to
Comparison of inflammation elicited in animals receiving various mass doses of UFCB and FCB suspended in BALF Figure 1
Comparison of inflammation elicited in animals receiving various mass doses of UFCB and FCB suspended in 
BALF. A comparison of inflammation elicited in animals receiving various mass doses of UFCB and FCB suspended in BALF at 
1 day (Panel A), 7 days (Panel B), and 42 days (Panel C) post-exposure. Rats were exposed to various mass doses of UFCB and 
FCB by intratracheal instillation. Animals were euthanized at 1 day, 7 days, and 42 days post-exposure, and bronchoalveolar 
lavage was performed. Inflammation was assessed by BAL PMN counts. Values are increased PMN number above the BALF 
control and are given as means ± SEM of 8 rats. Control PMN values were 1.45 ± 0.22 × 106, 1.09 ± 0.14 × 106, and 1.01 ± 0.14 
× 106 cells/rat for 1, 7 and 42 days respectively. Linear regression analysis with a 95% confidence interval reveals that on a mass 
dose basis UFCB causes significantly more inflammation than FCB at all post-exposure time points. On a mass dose basis, 
UFCB is shown to be approximately 65 times more potent than the FCB at all post-exposure time points. * indicates a signifi-
cant increase from control (p < 0.05; ANOVA).
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assess air/blood barrier injury. Exposure to either UFCB or
FCB caused a dose dependent cytotoxicity which declined
with time post-exposure (data similar to figure 1 not
shown). However, at the high dose, LDH activity
remained significantly elevated over control at all post-
exposure time points (Table 1). Effects on albumin levels
showed the same trend as LDH activity, with exposure to
the high dose of both UFCB and FCB causing a significant
increase in albumin levels over control at all post-expo-
sure time points (Table 1). On a mass dose basis, a signif-
icantly greater mass dose of FCB (65 fold higher) was
required at all post-exposure time points, to obtain the
same responses as seen with UFCB exposure in regards to
LDH activity and albumin levels (Table 2). However,
when dose was normalized to surface area of particles
administered, the UFCB exposure produced LDH activity
and albumin levels that were at most only 2-fold greater
than the FCB exposure at all post-exposure time points
analyzed (Table 2). When dose-response curves assessing
LDH activity and albumin levels based on surface area of
particles administered between UFCB and FCB exposure
were assessed using a linear regression curve analysis with
a 95% confidence interval (data similar to figure 2 not
shown), there was no significant difference between the
two curves at any post-exposure time points.
IL-1β, TNF-α, and MIP-2 mediator levels in the BAL were
also measured for UFCB and FCB exposure at all post-
exposure time points. The highest dose of UFCB caused a
significant increase in these mediator levels over control
values at all post-exposure time points. However, FCB
exposure did not increase mediator levels significantly
over control at any post-exposure time point (Table 1).
For all three mediators, a significantly greater mass dose of
FCB (130 fold higher) was required to obtain the compa-
rable mediator levels as elicited by UFCB exposure (Table
2). However, when dose was normalized to surface area of
particles administered, TNF-α and MIP-2 levels produced
by UFCB exposure were at most only 1.5 or 1.7 fold
greater than FCB levels. IL-1β cytokine levels for UFCB
exposure were at most only 2.6 fold greater than FCB IL-
1β cytokine levels (Table 2). Dose response curves assess-
ing TNF-α, IL-1β, and MIP-2 mediator levels based on sur-
face area of particles administered between UFTiO2 and
Table 1: Effect of Exposure to UFCB vs. FCB (High Dose) on pulmonary responses.
Parameter Group 1 day 7 days 42 days
PMN (106) Control 1.5 ± 0.2 1.1 ± 0.1 1.0 ± 0.1
UFCB high 22.1 ± 0.8* 8.1 ± 0.3* 4.2 ± 0.7*
FCB high 15.5 ± 0.4* 5.7 ± 0.2* 3.3 ± 0.2*
LDH (U/l) Control 49.3 ± 1.4 43.8 ± 0.8 45.1 ± 1.7
UFCB high 179.1 ± 6* 116.3 ± 4* 84.6 ± 2*
FCB high 135.3 ± 6* 88.6 ± 2* 71.9 ± 1*
Albumin (mg/ml) Control 0.21 ± 0.1 0.12 ± 0.01 0.18 ± 0.02
UFCB high 0.48 ± 0.02* 0.31 ± 0.025* 0.32 ± 0.01*
FCB high 0.40 ± 0.01* 0.25 ± 0.01* 0.26 ± 0.01*
TNF-α (pg/ml) Control 24.8 ± 0.5 28.2 ± 0.6 32.2 ± 0.6
UFCB high 45.3 ± 2* 50.4 ± 1* 60.1 ± 1*
FCB high 30.9 ± 0.8 34.3 ± 1 38.6 ± 0.9
MIP-2 (pg/ml) Control 437.7 ± 14 497.2 ± 22 476.5 ± 22
UFCB high 544.1 ± 34* 727.8 ± 29* 615.2 ± 21*
FCB high 384.9 ± 22 485.8 ± 22 532.9 ± 22
IL-1β (pg/ml) Control 58.1 ± 4 69.7 ± 5 70.5 ± 7
UFCB high 184.9 ± 10* 213.6 ± 8* 262.8 ± 9*
FCB high 78.6 ± 6 83.7 ± 9 115.7 ± 12
Zym. Stim. Chemi. Control 3.14 ± .08 3.06 ± .09 3.22 ± .30
UFCB high 7.28 ± .13* 5.35 ± .12* 3.85 ± .55
FCB high 4.48 ± .10* 4.06 ± .04* 2.96 ± 41
NO Dep. Chemi. Control 0.68 ± .05 0.52 ± .06 0.49 ± .07
UFCB high 4.2 ± .06* 3.6 ± .05* 2.4 ± .40*
FCB high 4.0 ± .04* 1.7 ± .05* 1.3 ± .04
* denotes that the change from control is statistically significant (p < 0.05) using ANOVA.Particle and Fibre Toxicology 2009, 6:15 http://www.particleandfibretoxicology.com/content/6/1/15
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FTiO2 exposure were assessed using a linear regression
curve analysis with a 95% confidence interval (data simi-
lar to figure 2 not shown). This analysis showed there was
no significant difference for any of the mediators between
the two curves at any post-exposure time point.
Alveolar macrophage zymosan-stimulated and NO
dependent chemiluminescence were measured to assess
reactive oxygen species production after UFCB and FCB
exposures. UFCB and FCB both caused dose-dependent
and transient increases in zymosan-stimulated chemilu-
minescence, which returned to control levels by 42 days
post-exposure (Table 1). A significantly greater mass dose
of FCB (130 fold higher) was required to produce compa-
rable zymosan-stimulated chemiluminescence levels as
elicited by UFCB exposure at all post-exposure times
(Table 2). However, when dose was normalized to surface
area of particles administered, UFCB zymosan-stimulated
chemiluminescence levels were only 1.2 to 1.8-fold higher
than FCB zymosan-stimulated chemiluminescence levels
(Table 2). On a mass dose basis, in regards to NO-depend-
ent chemiluminescence levels, UFCB was 68 times more
potent than FCB at 1 day post-exposure and was 130 fold
more potent at 7 and 42 days post-exposure. However,
when dose was normalized to surface area of particles
administered, UFCB NO-dependent chemiluminescence
levels were only 1.5-fold greater than FCB at 1 day post-
exposure and 3 fold greater at 42 days post-exposure
(Table 2). When the surface area zymosan-stimulated or
NO-dependent chemiluminescence dose-response curves
were analyzed using a linear regression curve with a 95%
confidence interval (data similar to figure 2 not shown),
there was no significant difference between the UFCB and
FCB dose-response curves at any post-exposure time
point.
Comparison of ultrafine carbon black and ultrafine 
titanium dioxide potency over 42 days
Both UFTiO2 and UFCB caused a dose dependent increase
in lavagable PMN. At 1 day post-exposure the inflamma-
tory activity of UFTiO2 (Figure 3 Panel A), indicated by
PMN number, is similar to the inflammatory potential of
equivalent surface area doses of UFCB (Figure 3 Panel B).
However, at 7 days post-exposure, the PMN number elic-
ited by UFCB exposure begins to decrease substantially
and continues to decrease over the 42 day post-exposure
time period. In contrast, PMN infiltration in response to
UFTiO2 increased slightly from day 1 to day 7 post-expo-
sure and only slightly decreased at the 42 days post-expo-
sure time period (Figure 3 Panel A).
The same trend is seen when comparing the BALF albu-
min levels elicited by UFCB and UFTiO2 exposure. Albu-
min levels for equivalent surface area doses of UFCB and
UFTiO2 are similar at 1 day post-exposure. However, for
UFTiO2 the albumin levels continue to increase slightly at
7 days and then decrease slightly back to 1 day levels at 42
days post-exposure. For UFCB exposure, albumin levels at
7 days begin to decrease and continue to decrease through
the 42 day post-exposure time period (Figure 4).
LDH activity in BALF elicited by UFCB was lower than
LDH activity elicited by UFTiO2 at all post-exposure time
points. For UFCB, LDH activity was highest at one day
post-exposure and decreased throughout the 42 day post-
exposure time period. LDH activity for UFTiO2 increased
at 1 day post-exposure, was sustained at 7 days post-expo-
sure, and only began to decrease slightly at 42 days post-
exposure (Figure 5).
Discussion
The proposed adverse health effects associated with the
inhalation of airborne ultrafine or nanoparticles from par-
ticulate matter air pollution or from exposure to engi-
neered nanoparticles are topics of ongoing scientific and
public concern [16,17]. For analyzing the possible toxicity
of nanoparticles, it is necessary to utilize a dose metric
that will accurately assess the particles' potential to cause
a change in toxicity parameters. Previous toxicity studies
have emphasized mass of particles administered as the
primary dose metric. However, data from the present
study indicate that, for low toxicity low solubility materi-
Table 2: Potency difference between UFCB and FCB when 
analyzed on a mass vs. surface area.
Parameter Dose Metric 1 Day 7 Days 42 Days
PMN (106)
Mass 65 65 65
Surface Area 2 1.5 1.6
LDH (U/l)
Mass 65 65 65
Surface Area 1.5 2 1.8
Albumin
Mass 65 65 65
Surface Area 1.5 2 2
TNF-α (pg/ml)
Mass 130 130 130
Surface Area 1.4 1.5 1.5
MIP-2 (pg/ml)
Mass 130 130 130
Surface Area 1.4 1.7 1.3
IL-1β (pg/ml)
Mass 130 130 130
Surface Area 2.4 2.6 2.3
Zym. Stim. Chemi.
Mass 130 130 130
Surface Area 1.5 1.75 1.2
NO Dep. Chemi.
Mass 68 130 130
Surface Area 1.5 2.5 3
Comparison of UFCB and FCB potency differences.Particle and Fibre Toxicology 2009, 6:15 http://www.particleandfibretoxicology.com/content/6/1/15
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als, surface area of particles administered appears an
appropriate dose metric in studies assessing pulmonary
toxicity of nanoparticles.
Data from the present study indicate that when carbon
black particles are administered on a mass dose basis,
UFCB particles have a significantly greater potential to
cause pulmonary inflammation and damage than FCB
particles of the same composition. However, when doses
of the ultrafine and fine carbon black are normalized to
surface area of particles administered, the difference in
responses of the two particle sizes becomes non-signifi-
cant. Our laboratory has reported similar results when
comparing pulmonary response to ultrafine and fine tita-
nium dioxide [18]. This, therefore, indicates that, for low
toxicity low solubility materials, surface area of particles
rather than mass maybe an appropriate dose metric when
analyzing nanoparticle toxicity.
A study conducted by Donaldson et al. [10], compared the
toxicity of ultrafine and fine particles. UFCB (14 nm) and
FCB (260 nm) were instilled into rat lungs based on an
equal mass dose. BAL was performed at 6 hours post-
exposure and inflammation was assessed by measuring
PMN number. Donaldson et al. [10] showed that on a
mass basis UFCB caused substantially more inflammation
than FCB. In a recent study by Duffin et al. [19], the
inflammatory potential of UFCB and UFTiO2 was greater
than the fine size analogs on an equivalent mass basis.
However, the potency of the ultrafine and fine particles
was found to be similar when the intratracheally instilled
dose to rats was normalized to equivalent particle surface
area delivered. Recently, a study by Stoeger et al. [20] uti-
lized six different types of ultrafine carbon particles. The
BET-specific surface areas ranged about 35 to 800 m2/g,
and the mean particle sizes ranged from 10 to 45 nm. This
study found that, while the inflammatory potential of
these six different particles was dependent on particle
type, potency was most strongly related to the BET surface
area [20]. These findings support the results of the current
study. The results indicate that particle surface area is a
critical driver of the cytotoxic and inflammatory potential
of nanoparticles. In contrast, Warheit et al. [8,9] reported
that intratracheal instillation of fine or ultrafine TiO2
resulted in similar levels of acute inflammation and cyto-
toxicity. They argued that these results were at variance
with the "conventional wisdom" that nano-sized parti-
cles, due to their larger surface area, are more toxic than
fine-sized particles of the same composition. These results
conflict with a study from our lab comparing the pulmo-
nary response over a 42 day post-exposure period to
intratracheal instillation of ultrafine vs fine TiO2 [18].
Comparison of inflammation elicited in animals receiving UFCB and FCB normalized to surface area of particles administered  per surface area of alveolar epithelium Figure 2
Comparison of inflammation elicited in animals receiving UFCB and FCB normalized to surface area of parti-
cles administered per surface area of alveolar epithelium. A comparison of inflammation elicited in animals receiving 
doses (0.0313, 0.0625 and 0.125 cm2/cm2) of UFCB and FCB normalized to surface area of particles administered per surface 
area of alveolar epithelium at 1 day (Panel A), 7 days (Panel B), and 42 days (Panel C) post-exposure. Particles were suspended 
in BALF. Alveolar epithelial surface area for the rat was taken from Stone et al. [14]. Rats were exposed to various doses of 
UFCB and FCB by intratracheal instillation. Animals were euthanized at 1 day, 7 days, and 42 days post-exposure and broncho-
alveolar lavage was performed. Inflammation was assessed by BAL PMN counts. Values are increased PMN number above the 
BALF control and are given as means ± SEM of 8 rats. Control PMN values were 1.45 ± 0.22 × 106, 1.09 ± 0.14 × 106, and 1.01 
± 0.14 × 106 cells/rat for 1, 7 and 42 days respectively. Linear regression analysis with a 95% confidence interval reveals that 
when dose is normalized to surface area of particles administered, dose responses curves assessing inflammation caused by 
UFCB and FCB exposure are not significantly different. On a dose normalized to surface area UFCB elicits at most a 2 fold 
increase in inflammation when compared to FCB at all post-exposure time points.
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Results of this study are very similar to the current study
with CB, indicating that ultrafine TiO2 was more potent
that fine TiO2 on a mass dose basis, but potencies were
similar when exposure was expressed on an equivalent
surface area of particles delivered basis. The failure of War-
heit and colleagues to observe this relationship is most
likely due to severe agglomeration of UFTiO2 in their stud-
ies, as noted by their dynamic light scattering data indicat-
ing that both fine and ultrafine TiO2 suspended in PBS
exhibited a mean diameter in excess of 2 μm. In contrast,
with the current study and that by Sager et al. [18] with
TiO2, particles were suspended in BALF, which greatly
improved dispersion and, thus, effective particle surface
area delivered [21]. Indeed, Shvedova et al. [22] reported
that improved dispersion of ultrafine carbon black
(UFCB) particles in BAL fluid increased the inflammatory
and damage potency compared to UFCB suspended in
PBS; i.e., intratracheal instillation of a 30 fold greater mass
of poorly dispersed UFCB suspended in PBS was required
to attain the same level of pulmonary damage (LDH activ-
ity) and inflammation (PMN level) as well dispersed
UFCB suspended in BAL fluid in a rat model.
As noted above, suspension of UFCB and UFTiO2 in BAL
fluid greatly improved dispersion of these nanoparticles.
Evidence cited above indicates that improved dispersion
increases the bioactivity of tested nanoparticles. An issue
is whether a poorly dispersed or a well dispersed nanopar-
ticle suspension more closely represents aerosol sizes gen-
erated in the workplace. Data from our laboratory
indicate that suspension of UFTiO2 in BAL fluid results in
a mean particle diameter of 204 nm, which is close to the
count mode aerodynamic diameter for UFTiO2 (138 nm)
generated from a dry bulk sample by an acoustical gener-
ator [23,24]. Furthermore, structure sizes of multi-walled
carbon nanotubes (MWCNT) determined by electron
microscopic analysis of MWCNT suspended in a disper-
sion medium which mimics BAL fluid closely resemble
structures generated from a dry bulk sample by an acous-
tical generator [23,25]. In addition, structure morphology
Comparison of inflammatory potential of low, medium and high doses of UFTiO2 (Panel A) and UFCB (Panel B) at the various  post-exposure time points Figure 3
Comparison of inflammatory potential of low, medium and high doses of UFTiO2 (Panel A) and UFCB (Panel 
B) at the various post-exposure time points. A comparison of inflammatory potential of low, medium and high doses of 
UFTiO2 (Panel A) and UFCB (Panel B) at the various post-exposure time points. Rats were exposed to various mass doses of 
UFTiO2 (0.26, 0.52 and 1.04 mg/rat) and UFCB (0.047, 0.094, and 0.188 mg/rat) by intratracheal instillation. These mass doses 
resulted in identical surface area doses (0.0313, 0.0625, and 0.125 cm2/cm2) of UFTiO2 and UFCB. Animals were euthanized at 
1 day, 7 days, and 42 days post-exposure and bronchoalveolar lavage was conducted. Inflammation was assessed by measuring 
PMN levels. Control PMN values were 1.37 × 106, 0.78 ± 0.074 × 106, 0.88 ± 0.095 × 106 cells/rat for the UFTiO2 study and 
1.45 ± 0.22 × 106, 1.09 ± 0.14 × 106, and 1.01 ± 0.14 × 106 cells/rat for the UFCB study at 1, 7 and 42 days, respectively. Values 
are the increases in PMN number above BALF control and are given as means ± SEM of 8 rats. * indicates that PMN levels for 
that group were significantly higher than control (p < 0.05) using ANOVA.
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of a MWCNT aerosol produced by this acoustical genera-
tor closely resembles that reported in a workplace during
production and use of MWCNT [2]. Therefore, it appears
that use of well dispersed nanoparticle suspensions for
evaluation of bioactivity is relevant for risk assessment of
workplace exposures.
In this study, BAL fluid, i.e., diluted alveolar lining fluid
was used to effectively disperse UFCB and UFTiO2. Porter
et al. [23] reported the use of dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC) and serum albumin in phos-
phate-buffered saline at concentrations found in BAL
fluid was also an effective dispersant for UFCB, UFTiO2,
and MWCNT. In contrast, DPPC alone was found to be an
ineffective dispersant [21,26]. Recently, Hessemann [27]
reported that serum albumin in phosphate-buffered
saline was an effective dispersion medium for UFTiO2.
However, concentrations of albumin required when used
alone rather than in combination with DPPC are likely
high enough to substantially coat the nanoparticles,
which may alter surface activity. In contrast, the combina-
tion of DPPC and albumin at the low levels found in the
BAL fluid did not alter the bioactivity of crystalline silica
in a rat or mouse model [21,23].
The post-exposure time point comparison of equivalent
particle surface area doses of UFCB and UFTiO2 indicates
that at 1 day post-exposure UFCB and UFTiO2 produce
similar inflammation, cytotoxicity, and air/blood barrier
damage. However, as post-exposure time period increases,
the inflammation and lung injury caused by UFTiO2 was
sustained, while that for UFCB tended to resolve. This
indicates that UFTiO2 causes more persistent pulmonary
toxicity than UFCB exposure. Such persistent pulmonary
responses to UFTiO2 lead NIOSH to recommend an expo-
sure standard for UFTiO2 which was significantly lower
than that for fine TiO2 [4].
Conclusion
These results support the hypothesis that, for low toxicity
low solubility materials, surface area of particles adminis-
tered, not mass of particles, maybe a more appropriate
dose metric to assess to pulmonary inflammation nano-
particles. In addition, the data suggest that on an equiva-
A comparison of air/blood barrier injury induced by low, medium and high doses of UFTiO2 (Panel A) and UFCB (Panel B) at  the various post-exposure time points Figure 4
A comparison of air/blood barrier injury induced by low, medium and high doses of UFTiO2 (Panel A) and 
UFCB (Panel B) at the various post-exposure time points. Comparison of air/blood barrier injury induced by low, 
medium and high doses of UFTiO2 (Panel A) and UFCB (Panel B) at the various post-exposure time points. Rats were exposed 
to various mass doses of UFTiO2 (0.26, 0.52, and 1.04 mg/rat) and UFCB (0.047, 0.094, and 0.188 mg/rat) by intratracheal instil-
lation. These mass doses resulted in identical surface area doses (0.0313, 0.0625, and 0.125 cm2/cm2) of UFTiO2 and UFCB. 
Animals were euthanized at 1 day, 7 days, and 42 days post-exposure, and bronchoalveolar lavage was conducted. Air/blood 
barrier injury was assessed by measuring BALF albumin levels. Control values of albumin were 0.073 ± 0.033, 0.084 ± 0.003, 
and 0.098 ± 0.007 mg/ml for the UFTiO2 study and 0.205 ± 0.11, 0.105 ± 0.010, and 0.184 ± 0.016 mg/ml for the UFCB study 
at 1, 7 and 42 days, respectively. Values are the increases in albumin levels above the BALF control and are given as means ± 
SEM of 8 rats. * indicates that albumin levels for that group were significantly higher than control (p < 0.05) using ANOVA.
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lent surface area of particles delivered basis ultrafine
titanium dioxide appears more bioactive than ultrafine
carbon black.
Methods
Animals for in vivo exposures
The rats used for the in vivo experiments were male
Fischer CDF (F344/DuCrl) rats weighing 200–300 g (~10
weeks old at arrival) obtained from Charles Rivers
(Raleigh, NC). The animals were housed in an AAALAC-
accredited; specific pathogen-free, environmentally con-
trolled facility. The animals were monitored to be free of
endogenous viral pathogens, parasites, mycoplasms, Heli-
cobacter and CAR Bacillus. Animals were housed in venti-
lated cages which were provided HEPA-filtered air, with
Alpha-Dri virgin cellulose chips and hardwood Beta-chips
used as bedding. The rats were maintained on a ProLaB
3500 diet and tap water, both of which were provided ad
libitum.
Bronchoalveolar fluid collection for particle suspension 
media
Rats were euthanized with an i.p. injection of sodium
pentobarbital (> 100 mg/kg body weight) and exsangain-
ated by cutting the descending aorta. A tracheal cannula
was inserted and bronchoalveolar lavage was conducted
[28]. A 6 ml aliquot of cold Ca+2 and Mg+2-free phosphate-
buffered saline (PBS) was used for the lavage wash. The
cold PBS was flushed into and out of the lungs two times
before the bronchoalveolar lavage (BAL) was collected.
The BAL from five rats was combined and centrifuged at
600 × g for 10 minutes using a Sorvall RC 3B Plus centri-
fuge (Sorvall Thermo Electron Corporation, Asheville
NC). The supernatant was decanted into a new tube while
the pellet was discarded. This BAL fluid was then used as
the vehicle for particle suspensions. The BAL fluid was col-
lected fresh the same day that the particulate suspensions
were made.
A comparison of cytotoxicity of low, medium and high doses UFTiO2 (Panel A) and UFCB (Panel B) at the various post-expo- sure time points Figure 5
A comparison of cytotoxicity of low, medium and high doses UFTiO2 (Panel A) and UFCB (Panel B) at the var-
ious post-exposure time points. Comparison of cytotoxicity of low, medium and high doses UFTiO2 (Panel A) and UFCB 
(Panel B) at the various post-exposure time points. Rats were exposed to various mass doses of UFTiO2 (0.26, 0.52, and 1.04 
mg/rat) and UFCB (0.047, 0.094, and 0.188 mg/rat) by intratracheal instillation. These mass doses resulted in identical surface 
area doses (0.0313, 0.0625, and 0.125 cm2/cm2) of UFTiO2 and UFCB. Animals were euthanized at 1 day, 7 days, and 42 days 
post-exposure and bronchoalveolar lavage was conducted. Cytotoxicity was assessed by measuring LDH activity in BALF. Con-
trol values of LDH activity for the UFTiO2 study were 46.375 ± 2.24, 39.5 ± 1.35 and 37.25 ± 2.63 and for the UFCB study 
were 49.375 ± 1.46, 43.75 ± 0.840 and 45.125 ± 1.69 at 1, 7 and 42 days, respectively. Values are the increases in LDH activity 
above the BALF control and are given as means ± SEM of 8 rats. * indicates that LDH activity for that group was significantly 
higher than control groups (p < 0.05) using ANOVA.
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Particles
Ultrafine carbon black (UCB – Printex 90, primary parti-
cle size = 14 nm), fine carbon black (FCB-Arosperse 15 V,
primary partial size = 260 nm) and ultrafine titanium
dioxide (UFTiO2-Aeroxide TiO2 P-25, primary partial size
= 21 nm; an 80/20 mixture of anatase/rutile) were
obtained as a gift from the Degussa Corporation (Parsip-
pany, NJ).
Suspension of UFCB, FCB, and UFTiO2
UFCB, FCB, and UFTiO2 were suspended in rat BAL fluid
as described previously [21]. Briefly, each particle sample
was sieved using a Retsch AS 200 Sieve (Retsch GmbH,
Haan, Germany) through 1.18 mm, 250 μm, and 45 μm
mesh screens, and particle samples were weighed to
desired amounts. Each respective particle sample was then
suspended in the fresh rat BAL fluid to obtain the desired
concentration (mg/ml). Once the particles were added to
the suspension media, the suspensions were pulse soni-
cated with 5 individual pulses at a duty cycle setting of
10% and an output setting of 1 with a Branson 450 Soni-
fier probe sonicator (Branson Ultrasonics Corporation,
Danbury, CT). This method has been reported previously
to result in well dispersed suspensions as determined by
light and electron microscopy [21]. In a previous study,
our laboratory evaluated the diameter of UFCB and
UFTiO2 structures after suspension in BAL fluid using the
dynamic light scattering (DLS) technique. Mean diameter
of well dispersed UFCB was 131 ± 4 nm, while UFTiO2
was 204 ± 18 nm [23]. Microscopically, FCB dispersed in
BAL fluid exhibited structures less than 1 μm in diameter
on average [21].
In vivo exposures
To receive their respective dose of particles, each rat was
anesthetized with an intraperitoneal (i.p.) injection of
methohexital sodium (30–40 mg/kg body weight; Mon-
arch Pharmaceuticals, Bristol, TN). Each animal was then
instilled via intratracheal instillation (IT) using a 20-
gauage 4-inch ball tipped animal feeding needle. Each
animal was instilled with 0.3 ml of their respective dose of
UFCB, FCB or UFTiO2.
Bronchoalveolar lavage and cell differentials
At 24-hours, 7 days, and 42 days post-IT, the animals were
euthanized with an i.p. injection of sodium pentobarbital
(> 100 mg/kg body weight) and exsanguinated by cutting
the descending aorta. A tracheal cannula was inserted and
bronchoalveolar lavage (BAL) was conducted [28]. A 6 ml
aliquot of cold Ca+2 and Mg+2 free PBS was used for the
first lavage wash. The cold PBS was flushed into and out
of the lungs two times before the BAL fluid was collected.
After the first lavage wash was collected, the BAL contin-
ued with 8 ml aliquots of cold Ca+2 and Mg+2-free PBS
until an additional 80 ml of BAL was collected. The BAL
from all rats was then centrifuged at 600 × g for 10 min-
utes using a Sorvall RC 3B Plus centrifuge (Sorvall Thermo
Electron Corporation, Asheville NC). After centrifugation,
the supernatant from the first lavage wash was decanted
into a clean conical vial and stored on ice to be used for
cytotoxicity analysis. The remaining lavage wash superna-
tants were discarded, and the cells remaining were washed
with cold Ca+2 and Mg+2-free PBS and spun again at 600 ×
g for 10 minutes. After this, the supernatant was dis-
carded, and the cells were resuspended in 1 ml of HEPES-
buffered medium.
Using these BAL cell samples, counting of polymorpho-
nuclear neutrophils (PMN) and alveolar macrophages
(AM) was conducted to assess inflammation. The number
of AM and PMN was determined according to their
unique cell diameters, using an electronic cell counter
equipped with a cell sizing attachment (Beckman Coulter
Multisizer 3 Counter, Hialeah, FL).
BAL fluid lactate dehydrogenase activity and albumin 
concentration
The degree of cytotoxicity induced by the instilled parti-
cles was determined by lactate dehydrogenase (LDH)
activity in the BAL fluid. LDH activity was measured using
Roche COBAS MIRA Plus chemical analyzer (Roche Diag-
nostic Systems Inc., Branchburg, NJ) as described previ-
ously by our laboratory [28]. Albumin concentrations
were assessed to examine if instilled particle exposures
had compromised the integrity of the alveolar air/blood
barrier. The air/blood barrier damage was determined by
the concentration of albumin in the BAL fluid. Albumin
concentrations were also measured using a Cobas Fara II
Analyzer (Roche Diagonostic Systems, Montclair, NJ) as
previously described by our laboratory [28].
Mediator measurements in bronchoalveolar lavage fluid
The presences of inflammatory mediators present in the
BAL fluid were analyzed by enzyme-linked immunosorb-
ent assay (ELISA). The levels of mediators present were
measured using commercially available ELISA kits (Bio-
Source International Inc., Camarillo, CA). Three media-
tors were quantified: tumor necrosis factor-α (TNF-α),
interleukin (IL)-β, and macrophage-inflammatory pro-
tein-2 (MIP-2).
Zymosan-stimulated and NO-dependent alveolar 
macrophage chemiluminescence
Reactive oxygen species production was determined by
measuring AM chemiluminescence. According to Van
Dyke et al. [29], only AM will generate reactive oxygen
species in response to unopsonized zymosan in the
chemiluminescence assay procedure. The AM chemilumi-
nescence assay was conducted in the same manner as pre-
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AM chemiluminescence was determined by incubating
1.0 × 106 AM/ml at 37°C for 20 minutes, followed by the
addition of 5-amino-2,3-dihydro-1,4, phthalazinedione
(luminol) to a final concentration of 0.08 μg/ml. This was
then followed by the measurement of chemiluminescence
for 15 minutes at 37°C.
Zymosan-stimulated chemiluminescence (CL) was deter-
mined by adding unopsonized zymosan (2 mg/ml) to the
AM samples immediately prior to measurement of chemi-
luminescence. Zymosan-stimulated CL was calculated as
(CL with zymosan – resting CL). NO-dependent chemilu-
minescence was determined by adding the unopsonized
zymosan as well as N-nitro-L-arginine methyl ester HCL
(L-NAME) to the AM samples immediately prior to meas-
urement of chemiluminescence. NO-dependent CL was
calculated as (zymosan-stimulated CL without L-NAME –
zymosan-stimulated CL with L-NAME). Zymosan-stimu-
lated and NO-dependent chemiluminescence were both
measured using a Berthold automated luminometer
(Berthold Autolumat LB 953, EG&G, Gaithersburg, MD)
at 390–620 nm for 15 minutes.
Statistics
Statistical differences between control groups and treat-
ment groups for the in vivo experiments examining the
toxicity of carbon black and titanium dioxide were deter-
mined using an analysis of variance (ANOVA) with signif-
icance set at p ≤ 0.05. Individual means were compared
using the Student-Newman-Keuls Method multiple com-
parison procedure with an overall significance level of p ≤
0.05. In addition, linear regression curve analysis with a
95% confidence interval was conducted on the surface
area data of each pulmonary parameter measured.
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